SCHEMBL26694129

SCHEMBL26694129

Clc1cnc(OCc2ccccc2)c(SCc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.51
PLAU P00749 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
PIN1 Q13526 1/20 0.39
POLB P06746 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2C9 P11712 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2E1 P05181 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18601113 0.87 NR2E3 (0.43) SLC6A4MEN1KMT2AGAAMAPT
SCHEMBL20304607 0.86 MAPT (0.43) SLC6A4MEN1KMT2AGAAMAPT
SCHEMBL18601042 0.85 MEN1 (0.46) SLC6A4PLAUMEN1KMT2AGAA
SCHEMBL29838045 0.84 NPSR1 (0.42) SLC6A4PLAUMEN1KMT2AGAA
SCHEMBL26694307 0.84 NPSR1 (0.42) SLC6A4PLAUMEN1KMT2AGAA
SCHEMBL26693778 0.84 MEN1 (0.40) SLC6A4MEN1KMT2AGAAMAPT
SCHEMBL29837768 0.84 MEN1 (0.40) SLC6A4MEN1KMT2AGAAMAPT
SCHEMBL29837998 0.82 MEN1 (0.40) SLC6A4MEN1KMT2AGAAMAPT
SCHEMBL21047264 0.82 MEN1 (0.40) SLC6A4PLAUMEN1KMT2AGAA
SCHEMBL26693611 0.82 MEN1 (0.40) SLC6A4MEN1KMT2AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083897-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF HIBERCELL, INC. 2024-03-14 US disclosed
CN-117203206-A GCN2 modulating compounds and uses thereof 希伯塞尔股份有限公司 2023-12-08 CN disclosed
EP-4281182-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF Hibercell, Inc. (US) 2023-11-29 EP disclosed
WO-2022159746-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF HIBERCELL, INC. (US) 2022-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083897-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF EIF2AK4, GCN1, CLN6 SLC6A4 2265/4885PLAU 4668/4885MEN1 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.